The company itself is the constraint: demand outrunning its own ability to take it on, and management is spending to rai
The model's full reasoning — Q4 2021 call → NOWe need to determine if management conveys that the company's own capability is the binding limit on growth, and that they are actively spending/building/hiring to raise that limit now. Let's review the transcript for relevant statements. Jurgi Camblong: "We remain fixated on six key pillars to drive long-term growth and value creation." That's general. Peter Casasanto: "Biopharma represents a large opportunity for us given our cloud-based architecture and decentralized global model that allows us to ingest, harmonize, and analyze multimodal data." That's about opportunity. Ross Muken: "We saw continued strength across the board in Q4, with excellent execution and operational efficiencies setting us up for a strong end of the year." Not about capacity. Jurgi: "We are continuing to invest in our U.S. opportunity and firmly believe there is significant runway ahead of us." That's about investment but not specifically about capacity being the ceiling. Jurgi: "We are pleased with our progress off onboarding clinical customers in this region and are expecting several signed agreements with Tier 1 institutions in the coming months." That's about demand. Jurgi: "We recently appointed Ken Freedman as our Chief Revenue Officer to lead our global clinical sales efforts." That's about sales, not capacity. Jurgi: "We are encouraged with the momentum we see with users continuing to increase their consumption after experiencing the value of SOPHiA’s platform." That's about utilization. Jurgi: "We continue to provide platform users with frequent updates incorporating new features, new applications, unique modalities, and new services." That's about product innovation. Jurgi: "We are extremely excited about this product and believe it will further differentiate SOPHiA as a tech company." That's about product. Jurgi: "We are achieving great momentum with our partners in enabling our shared customer base to generate actionable insights." That's about partnerships. Jurgi: "We announced this month that we signed a letter of intent with Ambry Genetics... Our collaboration will be centered around our shared long-term focus of leveraging multimodal data to accelerate research and the understanding of human diseases." That's about partnership.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| TSSI | TSS, Inc. | Q4 2022 | 2023-04-03 | D |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| JBHT | J.B. Hunt Transport Services, Inc. | Q2 2022 | 2022-07-19 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| FORM | FormFactor, Inc. | Q4 2021 | 2022-02-02 | B |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| HNRG | Hallador Energy Company | Q3 2021 | 2021-11-09 | C+ |
| FSS | Federal Signal Corporation | Q1 2018 | 2018-05-12 | A |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| ZBH | Zimmer Biomet Holdings, Inc. | Q2 2017 | 2017-07-30 | F |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
ZBH · Q2 2017 → YESThe question is whether management conveys that the company's own ability to serve, supply, or take on business is the binding limit, and they're actively spending/building/hiring now to raise that li...YES The transcript shows management framing the Warsaw North Campus production delays and resulting back orders as the direct constraint on meeting existing customer demand and recapturing lost business, with steady market demand present but supply gating growth. They describe actively investing now in manufacturing remediation, quality enhancements, safety stock building, and sales force incentives and hires to restore full supply and return to offense, treating these as the central priority to expand capability and capture opportunities. This matches the criteria of internal capability as the binding limit and immediate action to raise it. The remediation is presented as urgent and ongoing rather than routine catch-up. The answer is YES.
FORM · Q4 2021 → YESThe question is whether management conveys that their own ability to serve/supply is the binding limit, and they're actively expanding now. YES The transcript shows management explicitly framing the company's internal limits—labor shortages in U.S. factories and extended lead times from sub-component delays—as the immediate ceiling on revenue growth, while simultaneously describing active, ongoing capital investments, facility expansions (Livermore), tool and labor additions, and supplier qualification efforts as the central priority to raise that ceiling and meet surging customer demand. This dual situation is presented as a present-tense reality driving the $850 million target path. The supply-chain component is acknowledged but subordinated to the claim that demand is outrunning current capability, and the build-out is treated as the key task ahead rather than routine maintenance.
FLUX · Q2 2022 → YESThe question is: Does management convey that the company's own ability to serve, supply, or take on business has become the binding limit on how big it can be right now — that real demand is pressing ...YES The transcript shows management explicitly framing the company's production capacity as the current binding limit: "We can’t build packs fast enough to keep up with the demand" and noting that supply-chain constraints (especially electronic components) are preventing them from serving the robust order flow and record backlog.